

Clinical trials of AdVEGF121

TrialResults-center www.trialresultscenter.org

1 peripheral vascular diseases

Trial	Treatments	Patients	Trials design and methods
AdVEGF121 vs placebo			
RAVE (Rajagopalan) , 2003 n=NA follow-up: 12 weeks	adenoviral vascular endothelial growth factor (VEGF) gene transfer (AdVEGF121) versus placebo	subjects with unilateral exercise-limiting intermittent claudication during 2 qualifying treadmill tests, with peak walking time between 1 to 10 minutes	double blind

More details and results :

- cell-based therapies for peripheral vascular diseases in all type of patients at <http://www.trialresultscenter.org/go-Q335>

References

RAVE (Rajagopalan), 2003:

Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. *Circulation* 2003;108:1933-8 [[14504183](#)] [10.1161/01.CIR.0000093398.16124.29](#)